Clinical evaluation of a new serum tumour marker CA 242 in pancreatic carcinoma

Pasanen, Pentti; Eskelinen, Matti; Partanen, Kaarina; Pikkarainen, P; Penttilä, Ilkka; Alhava, Esko

doi:10.1038/bjc.1992.154

Cited by 26 publications

(24 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The CEA test and CA 50 test performed equally well at high and low specificity levels (Figure 1). This analysis shows that the CA 242 test has a clear advantage over CEA and CA 50 because of its higher specificity, confirming thus the results of previous studies (Haglund et al, 1989;Kuusela et al, 1991;Nilsson et al, 1992;Pasanen et al, 1992).…”

Section: Discussionsupporting

confidence: 81%

“…We have previously reported the results of the CEA, CA 50 and CA 242 assays in detail (Pasanen et al, 1992 Figure 1. The sensitivity of each marker was determined at several specificity levels.…”

Section: Resultsmentioning

confidence: 99%

“…Serum CEA and CA 50 are among the most intensively studied tumour markers and their role as reference markers is established (Kalser et al, 1978;Hansen et al, 1974;Lindholm et al, 1983;Jalanko et al, 1985;Masson et al, 1990;Haglund et al, 1992). CA 242 is a novel tumour marker which has proved promising because of its high specificity (Haglund et al, 1989;Kuusela et al, 1991;Nilsson et al, 1992;Pasanen et al, 1992). Evaluation of these marker studies is often difficult because of variance and heterogenity of the reference populations, and perhaps this is one reason why the role of these markers in pancreatic cancer is not yet clearly established.…”

Section: Discussionmentioning

confidence: 99%

“…Clinical assessment, laboratory tests, and imaging methods (ultrasound, computed tomography and endoscopic retrograde cholangio-pancreatography) were performed as previously decribed (Pasanen et al, 1992). In addition, liver biopsy was obtained or secretin-cerulein test was performed if hepatocellular disease or chronic pancreatitis was suspected.…”

Section: Methodsmentioning

confidence: 99%

“…One hundred and ninety-three patients were included altogether. The patients have been previously described in detail (Pasanen et al, 1992). There were altogether 24 patients with the final diagnosis of carcinoma of the head of the pancreas and two patients with the diagnosis of carcinoma of the ampulla of Vater.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Receiver operating characteristic (ROC) curve analysis of the tumour markers CEA, CA 50 and CA 242 in pancreatic cancer; results from a prospective study

Pasanen

Eskelinen²,

Partanen³

et al. 1993

Br J Cancer

Self Cite

View full text Add to dashboard Cite

(normal value in our laboratory < 210 U I-) in relation to serum gamma glutamyltranspeptidase level above 100 IU I-(normal value in our laboratory < 32 U 1'), or liver-specific alkaline phosphatase elevated. In addition to these jaundiced or cholestatic patients the following patients were included: patients with a history of two or more episodes of acute pancreatitis, patients who had continuous or recurring abdominal pain with raised serum or urine amylase levels measured at least three times, patients who had been suspected to have a pancreatic tumour or chronic pancreatitis in ultrasound or computed, tomography examination. Exclusion criteria were: age less than 15 years, pregnancy, jaundice developing in the intensive care unit, a history of recent heart surgery, insufficient cooperation, acute alcoholic pancreatitis, disseminated malignancy, parenchymal liver disease diagnosed within 2 days of admission, need for emergency surgery. One hundred and ninety-three patients were included altogether. The patients have been previously described in detail (Pasanen et al., 1992). There were altogether 24 patients with the final diagnosis of carcinoma of the head of the pancreas and two patients with the diagnosis of carcinoma of the ampulla of Vater. MethodsClinical assessment, laboratory tests, and imaging methods (ultrasound, computed tomography and endoscopic retrograde cholangio-pancreatography) were performed as previously decribed (Pasanen et al., 1992). In addition, liver biopsy was obtained or secretin-cerulein test was performed if hepatocellular disease or chronic pancreatitis was suspected. All the patients involved in the study were scheduled for re-examination 6 months after entering the study, and the clinical data of the hospital records were reviewed retrospectively after a follow-up period of 2 years. The final diagnosis of a pancreatic cancer or cancer of the ampulla of Vater was based on histology in 16 cases, on cytology in three, on operative or endoscopic macroscopic morphologic findings in three, and on the imaging methods in four. The diagnosis of chronic pancreatitis was based on histology in seven cases, on cytology in one, on secretin-cerulein test in six, on the imaging methods in 14 and on clinical course of the disease in six.

show abstract

Section: Discussionsupporting

confidence: 81%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Receiver operating characteristic (ROC) curve analysis of the tumour markers CEA, CA 50 and CA 242 in pancreatic cancer; results from a prospective study

Pasanen

Eskelinen²,

Partanen³

et al. 1993

Br J Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

Clinical aspects of altered glycosylation of glycoproteins in cancer

1999

View full text Add to dashboard Cite

Tumour-associated trypsin inhibitor in the diagnosis of pancreatic carcinoma

Pasanen

Eskelinen

Partanen

et al. 1994

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

The serum values of tumour-associated trypsin inhibitor (TATI) were measured in a prospective series of 97 patients with jaundice, 36 patients with unjaundiced cholestasis and 21 patients with suspicion of chronic pancreatitis or a pancreatic tumour, to assess its value in diagnosing pancreatic cancer. There were altogether 15 patients with cancer of the pancreas and 2 patients with cancer of the papilla of Vater. The highest serum TATI values were noticed in patients with choledocholithiasis, and raised values were also seen in patients with malignant disease of the liver or bile ducts. In the patients with pancreatic cancer, chronic pancreatitis or benign liver disease, the serum TATI values showed lower levels. The sensitivity of TATI in diagnosing pancreatic cancer was 41.1% with a specificity of 63.5% and an efficiency of 61.0%. In comparison to carcinoembryonic antigen (CEA), carbohydrate antigens CA 50, CA 242, tissue polypeptide antigen and tissue polypeptide-specific antigen, TATI showed a lower diagnostic value. When TATI was analysed in combination with the other markers (two tests positive), the combination of CEA with TATI reached the highest specificity (95.6%), efficiency (89.6%) and positive likelihood ratio (9.3). The results suggest that the diagnostic value of TATI is inferior to that of the established markers, but because of its different nature, it may be of help when used in combination as a complementary serum tumour marker in the diagnosis of pancreatic cancer.

show abstract

Clinical evaluation of a new serum tumour marker CA 242 in pancreatic carcinoma

Abstract: (CEA)

Cited by 26 publications

References 14 publications

Receiver operating characteristic (ROC) curve analysis of the tumour markers CEA, CA 50 and CA 242 in pancreatic cancer; results from a prospective study

Receiver operating characteristic (ROC) curve analysis of the tumour markers CEA, CA 50 and CA 242 in pancreatic cancer; results from a prospective study

Clinical aspects of altered glycosylation of glycoproteins in cancer

Tumour-associated trypsin inhibitor in the diagnosis of pancreatic carcinoma

Contact Info

Product

Resources

About